# Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)

> **NCT02939820** · — · APPROVED_FOR_MARKETING · sponsor: **Alnylam Pharmaceuticals**

## Conditions studied

- TTR-mediated Amyloidosis
- Amyloidosis, Hereditary
- Amyloid Neuropathies, Familial
- Familial Amyloid Polyneuropathies
- Amyloid Neuropathies
- Amyloidosis, Hereditary, Transthyretin-Related

## Interventions

- **DRUG:** patisiran (ALN-TTR02)

## Key facts

- **NCT ID:** NCT02939820
- **Lead sponsor:** Alnylam Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2024-05-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02939820

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02939820, "Expanded Access Protocol of Patisiran for Patients With Hereditary ATTR Amyloidosis (hATTR)". Retrieved via AI Analytics 2026-06-15 from https://api.ai-analytics.org/clinical/NCT02939820. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*